Ashley Salamone
Primary Care · Baltimore, MDNPI 1811261050
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Ardelyx, Inc. at 43.9% of the total. Reporting peaked in 2024 at $10,646 and has fallen 98.7% since, to $142 in 2025. Among primary care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $78.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$6K
- AbbVie$5K
- Takeda Pharmaceuticals U.S.A., Inc.$584
- Johnson & Johnson$513
- Sanofi$193
- Braintree Laboratories, Inc.$156
- plus $1K from 18 others
What the payments were for
- Consulting fees$3,21526%
- Travel & lodging$5,09541%
- Food & beverage$4,24934%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 9 | $5,517 |
| AbbVie | 59 | $4,581 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $584 |
| Johnson & Johnson | 14 | $513 |
| Sanofi | 3 | $193 |
| Braintree Laboratories, Inc. | 3 | $156 |
| Bristol Myers Squibb | 6 | $132 |
| Ironwood Pharmaceuticals, Inc | 6 | $112 |
| Daiichi Sankyo Inc. | 4 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| Boehringer Ingelheim | 3 | $72 |
| QOL Medical, LLC | 2 | $71 |
| Aimmune Therapeutics, Inc. | 2 | $68 |
| Organon | 6 | $64 |
| Sandoz | 2 | $61 |
| Merck | 3 | $59 |
| Intercept Pharmaceuticals, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $19 |
| Celltrion USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,572 in reported general payments places this provider in the 95th percentile of 191 primary care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 25 | $124,738 |
| ZenpepLipase/Protease/Amylase | 13 | $48,064 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 275 | $5,497 |
| MovantikNaloxegol Oxalate | 12 | $4,692 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 48 | $2,784 |
| Pantoprazole Sodium | 109 | $2,172 |
| Famotidine | 57 | $1,182 |
| Esomeprazole Magnesium | 33 | $1,178 |
| Promethazine Hcl | 20 | $1,050 |
| Omeprazole | 56 | $917 |
| Colestipol Hcl | 12 | $907 |
| Dicyclomine Hcl | 45 | $890 |
| Nortriptyline Hcl | 23 | $356 |
| Pregabalin | 35 | $353 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 27 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $4,581 | $124,73825 claims |
| Aimmune Therapeutics, Inc.Zenpep | $68 | $48,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 primary care providers in Maryland.
Other primary care in Baltimore
- Ololade IkuomolaBaltimore$10K
- Yury MalachevskyBaltimore$7K
- Xiaohong JiangBaltimore$4K
- Caitlin SorciBaltimore$2K
- Valerie PetersonBaltimore$2K
- Cameron CampbellBaltimore$2K
- Jamie RomeroBaltimore$1K
- Tina DomineyBaltimore$1K
- Larissa BellBaltimore$1K
- Patricia GoodmanUppr Marlboro$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.